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Introduction
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer worldwide and the second most 
common cause of cancer-related mortality accord-
ing to the World Health Organization.1 The annual 
incidence rates vary depending on the geographic 
location with Eastern Asia and Sub-Saharan Africa 
having the highest incidence of HCC.1 Hepatitis B 
vaccination remains the best intervention to reduce 
the incidence of HCC in places where hepatitis B 
virus (HBV) is highly prevalent as demonstrated in 
Taiwan.2 In the United States, the incidence of 
HCC has been rising and is expected to peak in 
2030 with the highest increase in Hispanics, fol-
lowed by Blacks and then Whites, and a decrease 
in Asian Americans according to a recent analysis 
of the Surveillance Epidemiology End Results 
(SEER).3 Surgical intervention by resection or 
liver transplantation are the only curative options; 
however, only 10–23% of patients are surgical can-
didates at the time of presentation.4–7 Unfortunately, 
most patients present with advanced HCC and 
face a 1-year survival of 15–39% with limited treat-
ment options.8,9
In this review we highlight novel biomarkers and 
imaging tests that are being investigated to 
improve surveillance and early diagnosis of HCC. 
Ultimately, early diagnosis will provide more 
treatment options and lead to improved survival 
for patients with HCC.
Surveillance for HCC
The poor prognosis of HCC is largely related to late 
diagnosis. Historically, serum alpha-fetoprotein 
(AFP) and diagnostic imaging with computed 
tomography (CT) or magnetic resonance imaging 
(MRI) have been primary diagnostic modalities. 
However, the poor prognosis due to late diagnosis 
of HCC has proven unacceptable and, recently, 
significant efforts have been devoted to identifying 
patients with early stage HCC.
Presence of cirrhosis, chronic hepatitis B, and 
prior history of HCC are some of the factors 
involved in the decision to enter a patient into a 
surveillance program for HCC (Table 1).10 All 
major societies including the American Association 
for the Study of Liver Diseases (AASLD), the 
European Association for the Study of the Liver 
(EASL), and the Asian-Pacific Association for the 
Study of the Liver (APASL) agree on the impor-
tance of liver cancer surveillance with abdominal 
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imaging every 6 months. For example, The 
AASLD recommends HCC surveillance with a 
liver ultrasound with or without serum AFP every 
6 months.10 However, patients with Child’s class 
C cirrhosis are not recommended to enter a sur-
veillance program unless they are listed for liver 
transplantation given their low expected survival 
without transplantation.
A large meta-analysis showed HCC surveillance 
can lead to detection of HCC at an earlier stage 
resulting in improved survival [pooled odds 
ratio (OR) 1.9, 95% confidence interval (CI) 
1.67–2.17].11 The study also showed that 
patients who underwent HCC surveillance were 
more likely to have HCC detected at an earlier 
stage using Milan or Barcelona Clinic Liver 
Cancer (BCLC) criteria (OR 2.08, 95% CI 
1.88–2.33).11 Further more, patients diagnosed 
with HCC by surveillance were more likely to 
undergo curative treatment than those who pre-
sented symptomatically or were diagnosed inci-
dentally (OR 2.24, 95% CI 1.99–2.52).11 The 
pooled rate of receiving curative treatment among 
patients undergoing surveillance was 51.6% 
(95% CI 50.2–53%) and 23.7% (CI 22.8–
24.7%) in patients who presented symptomati-
cally or were diagnosed incidentally.
Despite the benefits of HCC surveillance, it is not 
often implemented. Entering into HCC surveil-
lance program requires awareness of disease stage 
or cirrhosis and the screening guidelines, ordering 
appropriate screening imaging studies as well as 
patient adherence of screening studies and frequen-
cies. Goldberg et al. highlighted the number of spe-
cialist visits by gastroenterology or infectious diseases 
in the first year after cirrhosis diagnosis being the 
strongest predictors for HCC surveillance.12 In addi-
tion, ultrasounds ordered more than 3 months in 
advance were less likely to be done. In fact, ultra-
sounds ordered more than 180 days from the due 
date were associated with 23% decreased odds of 
being performed.12 Primary care provider knowl-
edge level about the liver cancer and awareness of 
effective HCC therapies are also predictors for pur-
suing HCC surveillance according to McGowen et 
al.12 Patient’s understanding also plays an important 
role in screening for HCC. Farvadin et al. con-
structed a survey questionnaire for patients at high 
risk for HCC.13 The survey revealed that 48.6% of 
patients did not believe they need to undergo HCC 
surveillance if they eat a healthy diet and 34% of the 
patients surveyed believed they did not need to 
undergo HCC screening if they had a normal physi-
cal examination or absence of symptoms.13
Imaging
Ultrasound
Ultrasound has many advantages. It is widely 
available, inexpensive, almost risk free, and 
accepted by most patients compared with con-
trast imaging. It has a wide historical sensitivity of 
40–80% with a specificity of 82–100%.14–17 A 
recent meta-analysis revealed a poor ultrasound 
sensitivity of 47% (95% CI 33–61%) at detecting 
early HCC.17 However, the results of a traditional 
grayscale abdominal ultrasound are highly 
dependent on the expertise of its operator. In 
addition, obese patients pose a challenge to the 
ultrasound as the resolution of the images are 
highly affected by the presence of liver steatosis 
Table 1. Populations with HCC screening benefit. Modified from Marrero et al.10 
Asian male hepatitis B carriers over the age of 40
Asian women hepatitis B carriers over the age of 50
African and/or North American Blacks with hepatitis B
Hepatitis B carriers with a family history of HCC
Genetic Hemochromatosis with cirrhosis
Alpha-1 antitrypsin deficiency with cirrhosis
Cirrhosis due to other etiologies
Stage 4 PBC
HCC, hepatocellular carcinoma; PBC, primary biliary cholangitis.
WS Ayoub, J Steggerda et al.
journals.sagepub.com/home/tam 3
and subcutaneous fat. It is also important to note 
that a coarse liver echotexture can also make 
underlying liver lesions difficult to visualize. The 
size of the liver lesion also affects the sensitivity of 
the ultrasound (Table 2).
A recent study by Samylova et al.18 reported that 
the sensitivity of an abdominal ultrasound in the 
setting cirrhosis is worse in patients with body 
mass index (BMI) ⩾ 30 kg/m2 compared with 
BMI <30 kg/m2 (0.76 versus 0.86, p < 0.01) or 
in  patients with nonalcoholic steatohepatitis 
(NASH) compared with other etiologies (0.59 
versus 0.84, p < 0.02). The authors also investi-
gated whether addition of AFP to ultrasound in 
this cohort of patients improves the sensitivity of 
the ultrasound. They concluded that addition 
of AFP (using a cutoff ⩾ 20 ng/ml) significantly 
improved the sensitivity from 0.82 to 0.89 in 
patients with BMI >30 kg/m2. The sensitivity 
of  the combination of the ultrasound with 
AFP ⩾ 20 ng/ml in patients with NASH remained 
lower than in patients without NASH (0.72 versus 
0.91, p < 0.008). The addition of AFP to ultra-
sound had no significant effect on the sensitivity 
in patients with BMI ⩾ 30 kg/m2 compared with 
patients with BMI <30 kg/m2 (0.89 versus 0.90, 
p = 0.98). Furthermore, ultrasound missed up to 
41% of HCC lesions in patients with NASH and 
up to 10% in patients with BMI ⩾ 30 kg/m2.18 
Based on these findings, the authors suggested 
the use of cross-sectional imaging for obese 
patients or those with NASH. However, cross-
sectional imaging is not without risks. While pro-
viding clearer images, deeper tissue penetration, 
and improved diagnostic accuracy for HCC, it 
carries the risk of radiation exposure and nephro-
toxicity. The conclusion of the authors is in line 
with the recommendations of the ultrasound liver 
imaging reporting and data system (US LI-RADS) 
for screening and surveillance of HCC.19
The US LI-RADS emphasizes the importance of 
reporting on the quality of the ultrasound in every 
ultrasound report. In brief, the US LI-RADS 
advocates the presence of a detection score and a 
visualization score on every ultrasound report. 
The detection score consists of three categories: 
US-1 negative, US-2 subthreshold, and US-3 
positive. The visualization score refers to the 
expected sensitivity of the performed ultrasound 
and consists of three categories: visualization A 
(no or minimal limitations), visualization B (mod-
erate limitations), and visualization C (severe 
limitations). Visualization A refers to studies 
where the limitations are not expected to affect 
the sensitivity in the detection of underlying 
masses. Visualization B refers to situations where 
limitations may mildly decrease the sensitivity for 
detection of small masses as in the presence of 
intermediate heterogeneity of the liver or in situa-
tions where a small portion of the liver is not well 
seen. Visualization C is defined as a study with 
limitations that result in significant lowering of 
the sensitivity of the ultrasound. Such situations 
include the presence of marked heterogeneity of 
the liver parenchyma and absence of visualization 
of the majority of the diaphragm (50%) or greater 
than 50% of the liver.19 Such reporting can 
improve communication with patients, referring 
physicians and radiologists as well as improving 
patient care.
Contrast-enhanced CT and MRI
Unlike other malignancies, HCC can be diagnosed 
based on imaging characteristics on multiphasic 
CT and MRI. HCC is characterized by arterial 
enhancing phase followed by a washout phase on 
portal venous/delayed phase. Introduction of hepa-
tobiliary contrast agents [gadobenate dimeglumine 
(Gd-BOPTA, Multihance, Bracco, Milan, Italy) 
and gadoxetate dimeglumine (Gd-EOB-DTPA, 
Primovist in Europe and Eovist in the United 
States, Bayer Healthcare] has improved detection 
of HCC. While only 5% of the injected Gd-BOPTA 
is excreted into the biliary system, approximately 
50% of the Gd-EOB-DPTA undergoes biliary 
excretion improving the sensitivity of HCC detec-
tion by 5–15% with Gd-EOB-DPTA.20 MRI has 
a higher sensitivity than CT in diagnosing HCC, 
but the sensitivity varies according to the size of 
the liver nodule (Table 3). Overall, MRI has a 
sensitivity of 77–100% for detecting nodular 
HCC while CT has a sensitivity of 68–91%.21 
However, the sensitivity is only 45–80% with 
MRI and 40–75% with CT for lesions measuring 
1–2 cm and it is close to 100% for lesions larger 
Table 2. Abdominal ultrasound sensitivity according to nodule size.18
Size of liver tumor 1–2 cm 2–3 cm 4–5 cm >5 cm
Sensitivity 0.65 0.76 0.84 0.90
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than 2 cm.21 CT and MRI are not indicated as 
surveillance tests for HCC owing to their higher 
cost when compared with ultrasound. They also 
carry the risk of developing toxicity such as hyper-
sensitivity reaction, nephrogenic systemic fibrosis 
in patients with advanced renal disease receiving 
gadolinium-based contrast agents, concern about 
accumulation of gadolinium in the brain, and 
iodine-induced nephrotoxicity from the intrave-
nous contrast agents.20 In addition, CT is also 
associated with radiation exposure. Newly abbre-
viated protocols have been proposed to maximize 
the benefits of the cross-sectional MRI with limit-
ing contrast exposure.22,23 Such shortened proto-
cols involve T1-weighted imaging from the 
hepatobiliary phase after gadoxetate disodium 
infusion and T2-weighted imaging and diffusion-
weighted imaging. These abbreviated contrast 
MRI protocols have the potential to shorten MRI 
imaging times which could reduce costs and 
increase patient comfort.
Contrast-enhanced ultrasound
Contrast-enhanced ultrasound (CEUS) is an 
imaging modality that is superior to the grayscale 
ultrasound in terms of offering real-time visuali-
zation of contrast-enhanced images in the arte-
rial, portal-venous, and late phase. CEUS can be 
used to better characterize liver lesions identified 
on ultrasound, CT, or MRI but is not an appro-
priate imaging modality for HCC surveillance. 
The advantage of CEUS includes the ability to 
visualize the arterial and venous phases in real 
time through the use of micro bubbles. Micro 
bubble injections can be performed as many times 
as needed to obtain adequate imaging of a target 
lesion since the agent is nontoxic and is excreted 
through the lungs. The sensitivity and specificity 
of CEUS for HCC larger than 2 cm in diameter is 
also comparable with MRI and CT.20 A recent 
meta-analysis showed the pooled sensitivity and 
specificity of CEUS for the diagnosis of HCC as 
0.85 (95% CI 0.84–0.86) and 0.91 (95% CI 
Table 3. Sensitivity and specificity of selected studies and blood biomarkers for detecting hepatocellular 
carcinoma.15,16,21,24–29
Sensitivity Specificity
Ultrasound15,16 51–87% 80–100%
CT16,21 68–91% 87–98%
MRI16,21 77–100% 84–97%
Contrast enhanced ultrasound24 85% 91%
AFP 25–65% 80–94%
DCP 72.7% 90%
DCP + AFP 87% 69%
GP-3 55.1% 97%
GP-3 + AFP 75.5% 83.3%
miR-21 61.1% 83.3%
miR-15b 98.3% 15.3%
miR-130b 87.7% 81.4%
miR-122 87.5% 97–97.5%
miR-224 87.5% 97–97.5%
miR-122 + AFP 97.5% 100%
AFP, alpha-fetoprotein; CT, computed tomography; DCP, des-gamma-carboxyprothrombin; GP-3, glypican-3; miR, 
microRNAs; MRI, magnetic resonance imaging.
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0.90–0.92), respectively.24 CEUS has advantages 
over CT and MRI in being portable, radiation 
free, and does not rely on a potentially nephro-
toxic contrast agent.30–32 However, it has limited 
penetration of the liver parenchyma that can lead 
to missing deep liver lesions. It can overlook 
lesions in the subdiaphragmatic areas and mistake 
the falciform ligament and surrounding fat for 
lesions. CEUS can also give false positive results 
with scars, fibrosis, sarcoidosis, inflammatory 
pseudotumors, and necrosis.33
(18F)fluoro-2-deoxy-D-galactose positron 
emission tomography/computed tomography
Positron emission tomography (PET) with the 
glucose analogue 2-(8F)fluoro-2-deoxy-D-glucose 
(FDG) is not widely used in either diagnosis or 
surveillance for HCC. Its use was first demon-
strated in a small study of 39 patients with known 
or suspected HCC and demonstrated high speci-
ficity (100%).34 In the interim, several small stud-
ies have shown the utility FDGal PET in detecting 
HCC and HCC metastasis.35–37 However, PET 
has limited value in the diagnosis of HCC since 
most HCCs are not highly metabolically active. 
For this reason, PET can miss 30–50% of HCC 
lesions.20
Blood based biomarkers
Small molecules, such as proteins and nucleic 
acids, or tumor cells themselves that can be 
detected in the blood of patients could be excel-
lent diagnostic biomarkers for HCC. The devel-
opment of biomarkers is guided by the National 
Cancer Institute Early Detection Research 
Network (NCI-EDRN).38 This program involves 
five phases of investigation that range from Phase 
I, identification of potential biomarkers, to Phase 
V, randomized trials to determine whether bio-
markers can lead to early identification and reduc-
tion in mortality. This program carries potential 
biomarkers from bench to bedside and clinical 
application. However, only AFP have made it 
through all phases (Table 3).39
AFP
AFP was first discovered in the serum of patients 
with HCC in 1964 and has since been the pri-
mary diagnostic biomarker for HCC.40 AFP is 
primarily a protein of development and is highest 
during gestation, falling to trace levels after 
birth.41,42 High serum AFP has been shown to 
correlate with the presence and progression of 
HCC and it is used as both a diagnostic and prog-
nostic factor. Despite this, there are multiple 
problems using AFP as a diagnostic marker, such 
as elevation in non-HCC diseases, cirrhosis, hep-
atitis, cholangiocarcinoma, testicular germ cell 
tumor, and metastatic colon cancer.43 Further-
more, the sensitivity and specificity of AFP ranges 
from 25–65% and 80–94%, respectively.44,45 In 
fact, only about 60–80% of HCC have elevated 
AFP levels, leaving a large margin for false nega-
tives and missed diagnosis. It is for this reason 
that AFP alone is not recommended as the main 
screening test for HCC. Lectin-binding alpha-
fetoprotein (AFP-L3) is a subfraction of AFP. It 
has a high specificity of 99.4% for HCC and a low 
sensitivity of 18.8%.46 It has been shown that the 
levels of AFP and AFP-L3 can be detected in the 
blood 6 months prior to the diagnosis of HCC.47 
Adding AFP-L3 (cutoff 4%) increased the sensi-
tivity of the ultrasound to 94.3% compared with a 
sensitivity of 88.6% of ultrasound plus AFP (cut-
off >5 ng/ml). While sensitivity increased with the 
addition of AFP and AFP-L3 to the ultrasound, 
the specificity decreased from 96.4 to 82.7%.47 
Therefore, investigation of other new biomarkers 
is desperately needed.
Des-gamma-carboxyprothrombin
The development of proteomics research and 
high-throughput analyses has led to the identifi-
cation of multiple proteins that are upregulated in 
HCC and may provide potential biomarkers. 
Des-gamma-carboxyprothrombin (DCP), also 
known as prothrombin induced by vitamin K 
absence II (PIVKA II), is an abnormal prothrom-
bin molecule which is upregulated in HCC. 
Malignant transformation of hepatocytes and 
HCC are associated with alterations in post-
translational modifications (PTMs) of proteins. 
DCP is the result of altered vitamin-K-dependent 
carboxylation.48 DCP has been evaluated as a 
screening biomarker for HCC with mixed results. 
One benefit of DCP is that it is less likely to be 
elevated in non-HCC liver diseases than AFP. In 
a single study comparing patients with HCC with 
those with cirrhosis and chronic hepatitis, DCP 
had a sensitivity and specificity of 72.7% and 
90.0% for HCC, respectively.49
DCP and AFP
The combination of DCP and AFP was evaluated 
for the early diagnosis of HCC in a multicenter 
Therapeutic Advances in Medical Oncology 11
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case-control study by Lok et al.50 Results from 
this study showed the combination yielded an 
increase in sensitivity to 87% from 65% with AFP 
alone, but a decrease in specificity from 84% to 
69%. For screening purposes, this increase is sen-
sitivity is clearly beneficial and may prompt addi-
tional diagnostic studies. A separate case-control 
study from France compared cirrhotic controls 
against patients with HCC, of which 32 of 85 
patients (38%) had early stage HCC (classified as 
BCLC stage A).51 DCP alone showed an area 
under receiver operating characteristic curve 
(AUROC) of 0.81, 95% CI 0.70–0.92, and posi-
tive predictive value (PPV) of 77% for the diag-
nosis of HCC. The combination of DCP and 
AFP was found to have an AUROC of 0.83, 95% 
CI 0.72–0.93, indicating they may be useful for 
diagnosis in patients with cirrhosis. In a Chinese 
study of 120 patients with HCC, DCP alone was 
inferior to the combination of DCP+AFP by hav-
ing lower sensitivity (53.3% versus 78.3%) and 
specificity (85.6% versus 53.3%).52
Glypican-3
Glypican-3 (GPC3) is another protein which rep-
resents a potential biomarker for the diagnosis of 
HCC. GPC3 is involved in cell proliferation, sur-
vival, and tumor suppression.53 Normally absent 
in healthy hepatocytes, GPC3 is upregulated in 
HCC and is thought to participate in canonical 
Wnt signaling growth pathway.54,55 Similar to 
AFP, GPC3 is not present in all HCCs but is 
found in 33% of patients who were seronegative 
for both DCP and AFP.56 One study suggested 
that an acute rise in GPC3 suggests transition 
from premalignant liver lesion to HCC.57 Another 
benefit of GPC3 is its nonexpression in healthy 
hepatocytes and expression being independent of 
tumor size.58 A meta-analysis comparing GPC3 
to AFP expression in early tumors (defined as 
BCLC 0 or A, TNM stage 1) found GPC3 had 
sensitivity and specificity of 55.1% and 97.0% 
compared with 34.7% and 87.6% for AFP.25 In 
addition, combination of GPC3 and AFP 
increased sensitivity to 76% for diagnosis of HCC 
when tumors were <3 cm.
The GALAD model
The GALAD model incorporates AFP, AFP-L3, 
and DCP into a formula taking account age, sex, 
and gender of the patient. It is calculated as 
–10.08 + 1.67 × [gender (1 for male, 0 for 
female)] + 0.09 × [age] + 0.04 × [AFP-
L3] + 2.34 × log[AFP] + 1.33 × log[DCP].59 
It has been developed to predict the probability 
of having HCC in patients with chronic liver dis-
ease.59 The GALAD score has been validated in 
Germany, Japan, UK, and Hong Kong. It has 
recently been validated in the USA through a ret-
rospective study by Yang et al.60 When compared 
with ultrasound as a surveillance test, the GALAD 
score had a higher area under the curve (AUC) 
than ultrasound (0.95 versus 0.82; p < 0.01). A 
GALAD score of –1.18 had a sensitivity of 92%, 
specificity of 79% and AUC of 0.92 versus 0.82 
for an abdominal ultrasound (95% CI 0.88–0.96) 
for detecting early stage HCC defined as BCLC 
0-A).60 Even for AFP negative tumor, a cutoff of 
-1.18 was associated with a sensitivity of 89% 
and specificity of 81%.60
Biomarkers in development
Multiple proteins are upregulated in HCC and 
many have been previously identified and reported 
in the literature as potential biomarkers for diag-
nosis or early detection of HCC. Overall, the het-
erogeneity of HCC tumors and multiple different 
etiologies makes surveillance and diagnosis diffi-
cult based on serum protein levels alone. 
Therefore, identification of other small molecules 
has been of importance in HCC research.
Similar to the advancements in proteomics, tran-
scriptome analysis has promoted genomics 
research to identify nucleic acids in serum and 
tumor tissue which are upregulated in HCC and 
may serve as both novel biomarkers and therapeu-
tic targets. Perhaps the most notable of these 
nucleic acids are microRNAs (miRNA). miRNAs 
are small (17–25 nucleotides), noncoding RNAs 
that bind complementary sequences in target 
mRNA to induce degradation. In cancer, miRNAs 
may function as either tumor suppressor genes or 
oncogenes. Over 500 miRNA genes have been 
identified and found to affect multiple transcrip-
tional programs, including proliferation, differen-
tiation, and apoptosis. Xia et al. recently examined 
three large publicly available datasets, gene expres-
sion omnibus (GEO), Oncomine, and The Cancer 
Genome Atlas (TCGA), to identify 23 differen-
tially expressed genes targeted by 9 miRNAs and 
10 long noncoding RNAs (lncRNA) in HCC.61 
These databases contain gene expression data 
from tissue samples, not serum, making the results 
difficult to apply as biomarkers. However, these 
results are an example of the first step of biomarker 
investigation: identification of possible targets.
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Circulating miRNAs in the serum and plasma have 
been described as targets for biomarker analysis. 
Circulating miRNAs are a promising biomarkers 
for HCC as they are relatively stable and are pro-
tected from RNase activity in the pathogenesis of 
HCC.62,63 Patient-level studies have been con-
ducted for the diagnostic potential of serum miR-
NAs with encouraging findings (Table 3). A study 
of patients with hepatitis B or C was conducted to 
examine miR-21 serum expression and found it 
had 61.1% sensitivity and 83.3% specificity 
(AUROC = 0.773) in differentiating between 
patients with HCC and chronic hepatitis.26 The 
AUROC was 0.953 for differentiating those with 
HCC from healthy controls. A separate study eval-
uated patients from China with HCC, chronic 
hepatitis B, and healthy controls for the potential 
use of miR-15b and miR-130b as biomarkers for 
HCC detection.64 Analysis of these patients found 
miR-15b had the highest sensitivity reported 
(98.3%), however very low specificity (15.3%) 
while miR-130b had sensitivity and specificity of 
87.7% and 81.4%, respectively. Notably, the 
AUROC for miR-130b was very high (0.913) for 
detecting HCC amongst those with chronic hepa-
titis B and healthy controls. Lin et al. proposed and 
validated a serum miRNA classifier (seven differ-
entially expressed miRNAs: miR-29a, miR-29c, 
miR-133a, miR-143, miR-145, miR-192, and 
miR-505) to detect HCC in the training cohort, 
and two independent validation cohorts. miRNA 
classifier had higher sensitivity (range 70.4–85.7%) 
than did AFP of 20 (40.7–69.4%) to detect HCC, 
whereas its specificity (80.0–91.1%) was similar to 
that of AFP of 20 (84.9–100%). miRNA classifier 
had a larger AUC than did AFP to identify small-
size (AUC 0·833 [0.782–0.883] versus 0·727 
[0.664–0.792], p = 0.0018) and early stage (AUC 
0.824 [0.781–0.868] versus 0·754 [0.702–0.806], 
p = 0.015) HCC and could also detect AFP-
negative (AUC 0.825 [0.779–0.871]) HCC.27
More recently, Amr et al. evaluated the diagnostic 
potential of miR-122 and miR-224 in HCC and 
found that both had sensitivity of 87.5% and spe-
cificities of 97.0–97.5% for diagnosing early stage 
HCC (BCLC stage A4) compared with patients 
with chronic hepatitis.28 The diagnostic accuracy 
was 0.98 for miR-122 and 0.93 for miR-224. 
Compared with controls, accuracy for detecting 
HCC was 0.96 for miR-122 and 0.94 for miR-
224. Most notably, combining either miR-122 
with AFP yielded a sensitivity of 97.5%, specific-
ity of 100% and diagnostic accuracy of 1.0, better 
than any measure alone in this study.
MicroRNA are not the only nucleic acids studied 
as biomarkers for HCC. LncRNA have also been 
studied as potential biomarkers. Li et al. exam-
ined multiple databases to identify lncRNAs 
which were upregulated in HCC and then used 
serum samples from an independent cohort of 
HCC and control patients to evaluate their utility 
as biomarkers.29 Through this study, two lncR-
NAs were identified as potential biomarkers: 
HULC and Linc00152, both of which were 
upregulated in the plasma of patients with HCC. 
AUROC for diagnosis of HCC were 0.78 and 
0.85 for HULC and Linc00152, respectively. 
Combination of HULC and Linc00152 yielded 
an AUROC of 0.87 and the addition of AFP 
increased the AUROC to 0.89.
Despite the increased sensitivity, specificity, and 
AUROC associated with each of the miRNAs and 
lncRNAs above, there are multiple limitations to 
be overcome. Ideal biomarkers must have suffi-
cient sensitivity and specificity, but perhaps more 
importantly, must be widely available and cost-
effective for surveillance. While these small mol-
ecules perform well in studies, validation in large 
cohorts still needs to be performed and standard 
cutoffs for screening and diagnostic purposes 
need to be established. Furthermore, detection of 
these molecules requires real-time or quantitative 
polymerase chain reaction (PCR) for detection 
and quantification. The cost for isolation of 
miRNA, primers for processing and amplifica-
tion, and testing for quantification is sufficiently 
high that it may be difficult to apply on a large 
scale. Standardization of testing through the 
development of an assay that is widely available 
and easily processed with little opportunity for 
human error is paramount for establishing effec-
tive screening and diagnostic tests.
Liquid biopsy detects circulating tumor cells 
(CTCs), methylation status, mutation of specific 
tumor-related nucleic acids including DNA, 
RNA, and miRNAs originating from CTCs or 
being shed into the blood stream directly from liv-
ing or dying tumor cells.65 It consists of obtaining 
samples from different time points over the course 
of a disease in a minimally invasive manner. 
Ideally, such liquid biopsy offers the advantages 
of early detection of cancer, prediction of treat-
ment response, real-time monitoring for disease 
recurrence, and prediction of resistance to ther-
apy.66 Circulating tumor DNA (ctDNA) repre-
sents tumor-derived fragmented DNA in the 
bloodstream of cancer patients. Alteration of the 
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ctDNA associated genes such as p15, p16, APC, 
SPINT2, SFRP1, p16INK4a, TFPI2, GSTP1, 
and RASSF1A is linked to the development and 
progression of HCC.66,67 Reverse transcription 
(RT)-PCR was the first method used to detect 
CTCs in 1994. Since then, other enrichment 
techniques such as ISET technology, CanPatrol 
CATC analysis platform (SurExam, China), 
CellSearchTM, CTC-Chip, flow cytometry, and 
CanPatrolTM have been developed for CTC isola-
tion, characterization, prognosis assessment for 
metastasis, and efficacy of a drug.66 Many targets 
have been studied as potential valuable biomark-
ers for HCC assessment using these techniques. 
Such tumor-specific molecules include MAGE-1, 
MAGE-3, hTERT, GPC-3, CD133, CD90, 
K19, CD44, and PLAC1. However, the biomark-
ers lack specificity as they were also seen in other 
forms of malignancies in addition to HCC.50 In 
order for liquid biopsy to make it to clinical prac-
tice, it needs to overcome major hurdles. It needs 
to have standardized assay protocols and multi-
center validation studies.
Conclusion
Despite the advances in the field of HCC and the 
availability of surgical resection and liver trans-
plantation as curative measures for early HCC, 
screening and adherence to surveillance rates for 
HCC remain poor. Educating the gate keepers, 
that is, primary care physicians, health care asso-
ciates, and the population at risk, about HCC is 
an important factor in increasing the rate of early 
detection of HCC. Imaging studies, especially 
abdominal ultrasound, are currently the back-
bone for screening for HCC. Once a liver lesion is 
detected by an abdominal ultrasound in a patient 
at risk for development of HCC, it is followed by 
contrast imaging for confirmation, adding to the 
cost of HCC detection. Multiple studies have 
proven the cost effectiveness of screening for liver 
cancer with abdominal ultrasound. Combining 
biomarkers with abdominal ultrasound seems to 
be the next step in increasing the sensitivity and 
specificity of the screening test for HCC. 
However, such biomarkers need to be widely 
available, affordable, and easily accessible.
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